Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation -- Ignore unavailable to you. Want to Upgrade?

To: 9wald9 who wrote (420)	10/3/2004 1:04:35 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 557

I have not been following very closely Tgen's vaccine--from what I hear in the news, there is not likely to be a successful HIV vaccine-- the virus mutates too fast. As far as "proof of concept", AAV seems to have great promise as a means to express sequence information, whether it be gene therapy or a vaccine--AAV isn't associated with human disease etc etc. I don't want to steer you away from Tgen, I've owned this on and off longer than any other stock...but you should look into Cell Genesys and Ceregene--if you are interested in gene therapy and aav. As far as vaccines, if aav turns out to have a place, I'm not sure Tgen really has a lock on any IP that's worth much. Tgen stock would probably do awfully well if they showed some concrete results with their CF therapy. fwiw, I stumbled across this recently issued patent: 6,780,639, Antibiotic inducible/repressible genetic construct for gene therapy or gene immunization. --Might be of interest for those folks who follow Ariad.